Jeffrey V. Poulton Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

Jeffrey V. Poulton is EVP, Chief Financial Officer of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 47,751 shares of ALNY, which is worth approximately $12.9 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 1,264 shares (Common Stock) at a price of $245.33 per share, resulting in proceeds of $310,097. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 47.8K

55.82% 3M change

75.43% 12M change

Total Value Held $12.9 Million

Jeffrey V. Poulton Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$310,097 $245.33 p/Share	1,264 Reduced 2.58%	47,751 Common Stock
Mar 03 2025	BUY Grant, award, or other acquisition	-	15,117 Added 23.57%	49,015 Common Stock
Feb 28 2025	SELL Open market or private sale	$191,597 $240.7 p/Share	796 Reduced 2.29%	33,898 Common Stock
Feb 27 2025	BUY Exercise of conversion of derivative security	-	1,908 Added 5.21%	34,694 Common Stock
Feb 14 2025	SELL Open market or private sale	$249,611 $258.13 p/Share	967 Reduced 2.86%	32,786 Common Stock
Feb 13 2025	BUY Grant, award, or other acquisition	-	3,109 Added 8.43%	33,753 Common Stock
Nov 26 2024	SELL Open market or private sale	$421,088 $250.35 p/Share	1,682 Reduced 5.2%	30,644 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	-	3,434 Added 9.6%	32,326 Common Stock
Jun 25 2024	SELL Open market or private sale	$368,219 $229.42 p/Share	1,605 Reduced 5.26%	28,892 Common Stock
Jun 24 2024	BUY Grant, award, or other acquisition	-	3,278 Added 9.71%	30,497 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	7,741 Added 22.14%	27,219 Common Stock
Feb 28 2024	SELL Open market or private sale	$89,744 $156.35 p/Share	574 Reduced 2.86%	19,478 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	1,908 Added 8.69%	20,052 Common Stock
Feb 16 2024	SELL Open market or private sale	$149,297 $148.26 p/Share	1,007 Reduced 5.26%	18,144 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	3,278 Added 14.62%	19,151 Common Stock
Aug 04 2023	SELL Open market or private sale	$646,847 $186.95 p/Share	3,460 Reduced 17.9%	15,873 Common Stock
Aug 03 2023	BUY Grant, award, or other acquisition	-	7,627 Added 28.29%	19,333 Common Stock
Apr 27 2023	SELL Open market or private sale	$190,475 $194.96 p/Share	977 Reduced 7.7%	11,706 Common Stock
Apr 26 2023	BUY Grant, award, or other acquisition	-	3,277 Added 20.53%	12,683 Common Stock
Aug 04 2022	SELL Payment of exercise price or tax liability	$1,036,019 $204.99 p/Share	5,054 Reduced 34.95%	9,406 Common Stock
Aug 03 2022	BUY Grant, award, or other acquisition	-	11,325 Added 43.92%	14,460 Common Stock
Apr 20 2021	SELL Payment of exercise price or tax liability	$184,105 $133.12 p/Share	1,383 Reduced 30.61%	3,135 Common Stock
Apr 19 2021	BUY Grant, award, or other acquisition	-	4,518 Added 50.0%	4,518 Common Stock

Also insider at

FIXX

Homology Medicines, Inc. Healthcare

DFFN

Diffusion Pharmaceuticals Inc. Healthcare

Director

JVP